Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Conditions

• Solid Tumours

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Zongertinib — DRUG
  Zongertinib

Study Details

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

Key Dates

Start date

Oct 11, 2024

Status verified

Jun 2026

Primary completion

Dec 31, 2027

Completion

Dec 29, 2028

Study Design

Enrollment

430 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Zongertinib treatment

Primary Outcome Measure

Proportion of patients with objective response (OR) [ Time Frame: Up to 51 months ]

Central Contacts

• Boehringer Ingelheim
  1-800-243-0127
  [email protected]

Locations (20)

Find similar trials in Anchorage, AK

Related Studies

• A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
  PHASE1/PHASE2 · Recruiting · Orion Corporation, Orion Pharma · Los Angeles, California
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
  PHASE1 · Recruiting · Epkin · Beverly Hills, California
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
  PHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Irvine, California
• A Study of BI 3810944 in Patients With Advanced Cancer
  PHASE1 · Recruiting · Boehringer Ingelheim · Louisville, Kentucky